Phase XIV, group 1 - 01.09.2020 - 30.08.2023

Ca.-No 194

Antibody-based approaches to activate NK in cancer immunotherapy

Israeli Partner: Angel Porgador, Ben-Gurion University
German Partner: Frank Momburg, DKFZ

Ca.-No 195

Ferroptosis in cancer therapy: concepts and mechanisms

Israeli Partner: Sima Lev, Weizmann Institute
German Partner: Frank Westermann, DKFZ

Ca.-No 196

Targeting polo-like kinase 4 by PROTAC: a novel modality for cancer therapy

Israeli Partner: Gali Prag, Tel Aviv University
German Partner: Ingrid Hoffmann, DKFZ

Ca.-No 197

Dissecting gastrointestinal B cell heterogeneity function in their contribution to liver damage in NASH and subsequent HCC

Israeli Partner: Oren Parnas, Hebrew University
German Partner: Mathias Heikenwälder, DKFZ

Publications

Ca.-No 198

Involvement of heparanase, immune cells, and HPV in the pathogenesis of Head & Neck carcinoma

Israeli Partner: Israel Vlodavsky, Technion
German Partner: Angel Cid-Arregui, DKFZ

Publications

Ca.-No 199

The synergistic role of dual IL-1 and CCR5 Inhibition in colorectal cancer metastasis: a translational study

Israeli Partner: Ron Natan Apte, Elena Voronov, Ben-Gurion University
German Partner: Niels Halama, DKFZ, NCT

Formular

Formulardaten werden geladen ...